Metallodrug BOLD-100 receives FDA Orphan Drug Designation for treatment of gastric cancer
The ruthenium-based anticancer agent BOLD-100 just received an Orphan Drug Designation in the treatment of gastric (stomach) cancer from the U.S. Food and Drug Administration. The small molecule therapeutic originally developed ...
Jul 21, 2021
0
1